Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study
Journal of Infection · 2023-04 · 86 (4) · 352-360
DOI: 10.1016/j.jinf.2023.02.012 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Infection, 2023-04. Verfasst von Andrew Evans und 10 weiteren Autor:innen. Beteiligte Einrichtung: Health and Social Services Group, Welsh Government, Cathays Park, Cardiff CF10 3NQ, United Kingdom. Electronic address: Andrew.Evans@gov.wales. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Medical Research Council, Department of Health, Chief Scientist Office.
Abstract (Originalsprache)
OBJECTIVE: To compare the effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab with no treatment in preventing hospital admission or death in higher-risk patients infected with SARS-CoV-2 in the community. DESIGN: Retrospective cohort study of non-hospitalized adult patients with COVID-19 using the Secure Anonymised Information Linkage (SAIL) Databank. SETTING: A real-world cohort study was conducted within the SAIL Databank (a secure trusted research environment containing anonymised, individual, population-scale electronic health record (EHR) data) for the population of Wales, UK. PARTICIPANTS: Adult patients with COVID-19 in the community, at higher risk of hospitalization and death, testing positive for SARS-CoV-2 between 16th December 2021 and 22nd April 2022. INTERVENTIONS: Molnupiravir, nirmatrelvir-ritonavir, and sotrovimab given in the community by local health boards and the National Antiviral Service in Wales. MAIN OUTCOME MEASURES: All-cause admission to hospital or death within 28 days of a positive test for SARS-CoV-2. STATISTICAL ANALYSIS: Cox proportional hazard model with treatment status (treated/untreated) as a time-dependent covariate and adjusted for age, sex, number of comorbidities, Welsh Index of Multiple Deprivation, and vaccination status. Secondary subgroup analyses were by treatment type, number of comorbidities, and before and on or after 20th February 2022, when omicron BA.1 and omicron BA.2 were the dominant subvariants in Wales. RESULTS: Between 16th December 2021 and 22nd April 2022, 7013 higher-risk patients were eligible for inclusion in the study. Of these, 2040 received treatment with molnupiravir (359, 17.6%), nirmatrelvir-ritonavir (602, 29.5%), or sotrovimab (1079, 52.9%). Patients in the treatment group were younger (mean age 53 vs 57 years), had fewer comorbidities, and a higher proportion had received four or more doses of the COVID-19 vaccine (36.3% vs 17.6%). Within 28 days of a positive test, 628 (9.0%) patients were admitted to hospital or died (84 treated and 544 untreated). The primary analysis indicated a lower risk of hospitalization or death at any point within 28 days in treated participants compared to those not receiving treatment. The adjusted hazard rate was 35% (95% CI: 18-49%) lower in treated than untreated participants. There was no indication of the superiority of one treatment over another and no evidence of a reduction in risk of hospitalization or death within 28 days for patients with no or only one comorbidity. In patients treated with sotrovimab, the event rates before and on or after 20th February 2022 were similar (5.0% vs 4.9%) with no significant difference in the hazard ratios for sotrovimab between the time periods. CONCLUSIONS: In higher-risk adult patients in the community with COVID-19, those who received treatment with molnupiravir, nirmatrelvir-ritonavir, or sotrovimab were at lower risk of hospitalization or death than those not receiving treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Health and Social Services Group, Welsh Government, Cathays Park, Cardiff CF10 3NQ, United Kingdom. Electronic address: Andrew.Evans@gov.wales.
- Population Data Science, Swansea University Medical School, Faculty of Medicine, Health and Life Science, Swansea University, Singleton Park, Swansea SA2 8PP, United Kingdom. Electronic address: Cathy.Qi@swansea.ac.uk.
- Population Data Science, Swansea University Medical School, Faculty of Medicine, Health and Life Science, Swansea University, Singleton Park, Swansea SA2 8PP, United Kingdom. Electronic address: J.O.Adebayo@swansea.ac.u…
- School of Medicine, Cardiff University, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, United Kingdom. Electronic address: underwoodj7@cardiff.ac.uk.
- School of Medicine, Cardiff University, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, United Kingdom. Electronic address: Coulsonjm@cardiff.ac.uk.
- Population Data Science, Swansea University Medical School, Faculty of Medicine, Health and Life Science, Swansea University, Singleton Park, Swansea SA2 8PP, United Kingdom. Electronic address: r.bailey@swansea.ac.uk.
Förderung
- Medical Research Council
- Department of Health
- Chief Scientist Office
- British Heart Foundation
- Wellcome Trust
Zitieren
APA
Evans, A., Qi, C., Adebayo, J. O., Underwood, J., Coulson, J., Bailey, R., Lyons, R., Edwards, A., Cooper, A., John, G., & Akbari, A. (2023). Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study. Journal of Infection, 86(4), 352-360. https://doi.org/10.1016/j.jinf.2023.02.012
Vancouver
Evans A, Qi C, Adebayo JO, Underwood J, Coulson J, Bailey R, et al. Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study. Journal of Infection. 2023;86(4):352-360. doi:10.1016/j.jinf.2023.02.012
BibTeX
@article{Evans2023,
author = {Evans, Andrew and Qi, Cathy and Adebayo, Jubril Omololu and Underwood, Jonathan and Coulson, James and Bailey, Rowena and Lyons, Ronan and Edwards, Adrian and Cooper, Alison and John, Gareth and Akbari, Ashley},
title = {Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study},
journal = {Journal of Infection},
year = {2023},
volume = {86},
number = {4},
pages = {352--360},
doi = {10.1016/j.jinf.2023.02.012}
}
EUVIMED